World Academic Colloquium on Microbiome

World Academic Colloquium on Microbiome: 2019 / 2025

The IAG microbiome (Inter Academic Group) was born following the 1st World Academic Microbiome Colloquium Paris October 2017 at the request of the participants to continue and expand the approach undertaken.

It is a question of committing to advancing "medicine" on two important fronts for the future, namely mastery:

chronic diseases by personalizing diagnosis and treatment
infectious diseases with antibiotic resistance by deepening the new contribution of the microbiome to bacterioresistance

The Academies of Health (Medicine and Sciences) are committed to concrete action to provide a tangible response to:
The need to standardize and harmonize study methods and protocols as well as regulations.
The need for more and comparable studies on humans to answer the question of personalization to improve the diagnosis and treatment of chronic diseases.
How to individualize the best ways to solve the scourge of bacterioresistance.

In concrete terms, this action will make it possible to:

to publish in a White Paper the recommendations for standardization (June 2021)
to make an inventory of the studies carried out in order (June 2021) to have them carry out to demonstrate the contribution of the microbiome in the personalization of the diagnosis and treatment of chronic diseases (June 2025).
to indicate the best research methods to overcome bacterioresistance either by means of virome (phages) or genetics (June 2021) and have them carry out (June 2025)

This program will mobilize all researchers and clinicians leading in the study of microbiome

illus_program_overview

This program is split into 4 parts:

Part 1.
Chronic diseases: Harmonization & Standardization
Composed of 6 WG :

WG.1 Stool and bacteria logistics
WG.2 Methods of analysis
WG.4 Pharmaceuticals/Food
WG.5 Preclinical studies
WG.6 Clinical studies

Part 2.
Chronic diseases: Personalization
Composed of 2 WG :

WG.7 Definition of microbiomes
WG.8 Inventory of existing studies

Part 3.
Infectious diseases: Bacterio resistance
Composed of 1 WG :

WG.9 Antibiotic resistance

Part 4.
Training & Information

This transversal WG have 2 goals:
- 1st Goal : Training to professionals
- 2nd Goal : Information to public

> Contact Download the programCONTACT
claude.vincent@aprcmicrobiome.org

Stakeholders / Leaders

LUXEMBOURG: Pr. Fay Betsou
GERMANY: Pr. Peer Bork
U.S: Pr. Lita Proctor
FRANCE: Pr. Magali Cordaillat-Simmons
SWEDEN: Pr. Frederik Bäcked
U.S: Pr. James Versalovic
FRANCE: Pr. Joël Doré
CHINA & U.S: Pr. Liping Zhao
FRANCE: Pr. Philippe Sansonetti
FRANCE: Pr Karine Clément
FRANCE: Sophie Durand

Patronage

IAP Sicence Health Policy, The interacademic partnership

US: National Academy of Medicine
as represented by: Yasmina BELKAID

China: Chinese Academy of Engineering
as represented by: Lanjuan LI

France: Académie Nationale de Médecine
as represented by: Philippe SANSONETTI

France: Académie des sciences - Institut de France

Germany: National Akademie der Wissenschaften Leopoldina
as represented by: Per BORK

Sweden: Académie Royale
represented by: Frederik Bäcked

Belgium: Académie Royale de Médecine
as represented by: Nathalie Delzenne

Partnership

Industrial Partnership

Key premium partner

Major partnerPrefired partnerAnnual partner

Foundation partnership

Key foundation partnerMajor foundation partnerFoundation partner

Start up partnership

Collaborating start up partner

Start up partner